In the lipid arm of ACCORD, 5518 participants who were treated with open- label simvastatin to achieve LDL levels <80 mg/dL were ran- domized to receive either fenofibrate or placebo. Treatment with fenofibrate therapy led to significant decreases in triglyc- eride levels and increases in HDL levels, but no difference was seen between groups in the primary composite outcome of a major fatal or nonfatal cardiovascular event (HR, 0.92; 95% Subsequent subgroup analyses of the FIELD and ACCORD Lipid trials confirmed the safety of fenofibrate when used alone or in combination with a statin. Moreover, potential benefits with fenofibrate therapy were suggested in terms of decreasing cardiovascular risk among patients with the most pronounced dyslipidemia, including those with the highest levels of triglycerides and lowest levels After CABG, elevated triglyceride levels may increase the risk of postoperative adverse outcomes. In an observational study of >25000 patients who underwent primary isolated CABG between 1971 and 1998, investigators noted that a higher baseline triglyceride level at the time of surgery was significantly associated with a higher risk of repeat coronary revascularization (stent or reoperation) during long-term Similarly, Sprecher et al177 reported that higher triglyceride levels at the time of surgery were asso- ciated with significantly greater risk of mortality and worse event-free survival in a prospective study of 6602 CABG patients. Of interest, after CABG, women with high triglyc- eride levels have far worse long-term survival (HR, 1.5; 95% CI, 1.1 2.1) compared with men with high triglyceride levels (HR, 1.1; 95% CI, 0.9 1.3). 